Literature DB >> 9011476

Risk factors and prevention of hepatocellular carcinoma in HCV infection.

L Benvegnù1, A Alberti.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. Several risk factors for HCC development have been identified, including cirrhosis, hepatitis B virus (HBV) infection, and hepatitis C virus (HCV) infection. With regard to cirrhosis, multivariate analysis indicates that alcohol abuse, HBsAg positivity, and anti-HCV seropositivity are independent variables associated with an increased risk for HCC in the cirrhotic patient. A close relationship between chronic HBV infection and HCC has been established by epidemiological studies and laboratory investigations. Evidence indicates that HCV also plays a leading role in development of HCC. Most patients with HCV-related HCC develop the tumor as a consequence of long-standing infection accompanied by chronic and progressive liver damage. In our study of 290 consecutive patients with cirrhosis, patients with persistently elevated or fluctuating ALT levels had a significantly greater rate of HCC development. The mechanism of HCC development in HCV infection remains to be elucidated. The annual cumulative risk of developing HCC is approximately 1% in patients without cirrhosis at inclusion and 3-10% in those with cirrhosis, depending on the stage of cirrhosis and presence of etiological cofactors. Although some evidence suggests that patients infected with the HCV genotype 1b are at increased risk for development of more severe liver disease, including HCC, results of our prospective study do not support a difference between cirrhotic and noncirrhotic patients in terms of the natural course of cirrhosis and the rate of developing HCC based on genotype. Strategies to prevent HCV-related HCC include blood screening and treatment of chronic HCV infection with interferon-alpha. Recent studies suggest that interferon-alpha treatment may prevent the development of HCC in HCV infection. Further research is warranted.

Entities:  

Mesh:

Year:  1996        PMID: 9011476     DOI: 10.1007/bf02087876

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

1.  Prevalence of antibodies to hepatitis C virus in hepatocellular carcinoma.

Authors:  R G Simonetti; M Cottone; A Craxi'; L Pagliaro; M Rapicetta; P Chionne; A Costantino
Journal:  Lancet       Date:  1989-12-02       Impact factor: 79.321

2.  Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis.

Authors:  J Bruix; J M Barrera; X Calvet; G Ercilla; J Costa; J M Sanchez-Tapias; M Ventura; M Vall; M Bruguera; C Bru
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

3.  Hepatitis C-associated hepatocellular carcinoma.

Authors:  F Hasan; L J Jeffers; M De Medina; K R Reddy; T Parker; E R Schiff; M Houghton; Q L Choo; G Kuo
Journal:  Hepatology       Date:  1990-09       Impact factor: 17.425

4.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

5.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.

Authors:  K Ikeda; S Saitoh; I Koida; Y Arase; A Tsubota; K Chayama; H Kumada; M Kawanishi
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

6.  Hepatocellular carcinoma in Italian patients with cirrhosis.

Authors:  M Colombo; R de Franchis; E Del Ninno; A Sangiovanni; C De Fazio; M Tommasini; M F Donato; A Piva; V Di Carlo; N Dioguardi
Journal:  N Engl J Med       Date:  1991-09-05       Impact factor: 91.245

7.  Hepatitis C virus infection in hepatocellular carcinoma. Detection of plus-strand and minus-strand viral RNA.

Authors:  S Takeda; M Shibata; T Morishima; A Harada; A Nakao; H Takagi; Y Nagai
Journal:  Cancer       Date:  1992-11-01       Impact factor: 6.860

8.  Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities.

Authors:  E Silini; F Bono; A Cividini; A Cerino; S Bruno; S Rossi; G Belloni; B Brugnetti; E Civardi; L Salvaneschi
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

9.  Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

Authors:  S Nishiguchi; T Kuroki; S Nakatani; H Morimoto; T Takeda; S Nakajima; S Shiomi; S Seki; K Kobayashi; S Otani
Journal:  Lancet       Date:  1995-10-21       Impact factor: 79.321

10.  Use of confirmatory assays for diagnosis of hepatitis C viral infection in patients with hepatocellular carcinoma.

Authors:  A Mangia; D S Vallari; A M Di Bisceglie
Journal:  J Med Virol       Date:  1994-06       Impact factor: 2.327

View more
  4 in total

Review 1.  Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy.

Authors:  Koji Miyanishi; Toshifumi Hoki; Shingo Tanaka; Junji Kato
Journal:  World J Hepatol       Date:  2015-03-27

2.  Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C.

Authors:  Junji Kato; Koji Miyanishi; Masayoshi Kobune; Tokiko Nakamura; Kohichi Takada; Rishu Takimoto; Yutaka Kawano; Sho Takahashi; Minoru Takahashi; Yasushi Sato; Tetsuji Takayama; Yoshiro Niitsu
Journal:  J Gastroenterol       Date:  2007-10-15       Impact factor: 7.527

3.  Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK.

Authors:  C Canavan; J Eisenburg; L Meng; K Corey; C Hur
Journal:  Dig Dis Sci       Date:  2013-05-30       Impact factor: 3.199

4.  Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection.

Authors:  Valli De Re; Laura Gragnani; Elisa Fognani; Alessia Piluso; Francesco Izzo; Alessandra Mangia; Marina Crovatto; Graziella Gava; Pietro Casarin; Domenico Sansonno; Vito Racanelli; Salvatore De Vita; Pietro Pioltelli; Laura Caggiari; Mariangela De Zorzi; Massimiliano Berretta; Andrea Gini; Antonella Zucchetto; Franco Maria Buonaguro; Paolo De Paoli; Anna Linda Zignego
Journal:  Biomed Res Int       Date:  2014-02-26       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.